IFITM3: A Potential Drug Target and Biomarker (G10410)

Target Name: IFITM3

NCBI ID: G10410

IFITM3

IFITM3: A Potential Drug Target and Biomarker

Interferon-induced transmembrane protein 3 (IFITM3) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is a transmembrane protein that is expressed in various tissues and cells in the body and plays a critical role in cell signaling and inflammation.

IFITM3: Structure and Function

IFITM3 is a 21-kDa protein that is composed of 156 amino acid residues. It has a characteristic transmembrane domain and a N-terminal extracellular domain that is involved in its cell signaling functions. The transmembrane domain of IFITM3 is characterized by a putative ion channel that is involved in the regulation of cell signaling pathways, including the production of intracellular signaling molecules, such as cytokines and chemokines.

IFITM3 is involved in various signaling pathways that are important for the development and progression of diseases. For example, it is involved in the regulation of cell proliferation, differentiation, and survival, as well as in the regulation of cell migration and the development of cancer. It is also involved in the regulation of inflammation, including the regulation of immune cell function and the production of pro-inflammatory cytokines.

IFITM3 as a Drug Target

IFITM3 has been identified as a potential drug target for various diseases due to its involvement in various signaling pathways that are important for disease development. For example, studies have shown that IFITM3 is involved in the regulation of cancer cell proliferation and has been shown to inhibit the production of pro-inflammatory cytokines. Therefore, IFITM3 may be an effective target for cancer therapies that target these pathways.

IFITM3 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that IFITM3 is involved in the regulation of neurotransmitter release and cell signaling pathways that are important for the development and progression of these diseases. Therefore, IFITM3 may be an effective target for neurodegenerative therapies.

IFITM3 has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis and multiple sclerosis. Studies have shown that IFITM3 is involved in the regulation of immune cell function and the production of pro-inflammatory cytokines, which are important for the development and progression of these disorders. Therefore, IFITM3 may be an effective target for autoimmune therapies.

IFITM3 as a Biomarker

IFITM3 has also been shown to be involved in the regulation of various signaling pathways that are important for disease diagnosis and treatment. Therefore, IFITM3 may be an effective biomarker for various diseases. For example, IFITM3 has been shown to be involved in the regulation of cancer cell proliferation and has been shown to inhibit the production of pro-inflammatory cytokines. Therefore, IFITM3 may be an effective biomarker for cancer diagnostics and therapies.

IFITM3 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have shown that IFITM3 is involved in the regulation of neurotransmitter release and cell signaling pathways that are important for the development and progression of these diseases. Therefore, IFITM3 may be an effective biomarker for neurodegenerative diseases.

IFITM3 has also been shown to be involved in the regulation of autoimmune disorders, including

Protein Name: Interferon Induced Transmembrane Protein 3

Functions: IFN-induced antiviral protein which disrupts intracellular cholesterol homeostasis. Inhibits the entry of viruses to the host cell cytoplasm by preventing viral fusion with cholesterol depleted endosomes. May inactivate new enveloped viruses which buds out of the infected cell, by letting them go out with a cholesterol depleted membrane. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:26354436, PubMed:33270927, PubMed:33239446). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33270927). Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436). Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane (PubMed:33270927)

The "IFITM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFITM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets